Search clinical trials for: AG-221

Total 1891 results

Pfizer

Completed

Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer

Kidney Neoplasms

Korea, Republic of, United States, Canada, Spain, Italy, United Kingdom, China, Singapore, Slovakia, France, Japan, Australia, Germany, Taiwan, Brazil, Russian Federation, India, Poland, Austria, Greece, Ireland, Sweden
Pfizer

Terminated

PF-04856884 (CVX-060) In Combination With Axitinib In Patients With Previously Treated Metastatic Renal Cell Carcinoma

Metastatic Renal Cell Carcinoma

United States, Czechia
Chang Gung Memorial Hospital

Completed

Efficacy of Wound Care and Reduction of Wound Complications by Use of AQUACEL® Ag Surgical Dressing in MIS TKA

Postoperative Complication
University Hospital Heidelberg

Unknown

A Randomized Trial Comparing 2 Methods for Rapid Induction of Cooling in Stroke Patients, Cold Infusions vs. EMCOOLS Flex.Pads (iCOOL 2) (iCOOL 2)

Ischemic Stroke | Hemorrhagic Stroke

Germany
Creative Medical Technology Holdings Inc

Recruiting

Safety and Efficacy of CELZ-201 in Patients With Recent Onset Type 1 Diabetes (CREATE-1)

Diabetes Mellitus, Type 1 | Type 1 Diabetes

United States
Bayer

Recruiting

Study to Continue Treatment With Darolutamide in Patients Who Have Been Participating in Previous Darolutamide Studies Supported by Bayer

Cancer

Korea, Republic of, United States, China, Austria, Belgium, Brazil, Colombia, Czechia, Estonia, Finland, France, Germany, Hungary, Israel, Italy, Japan, Latvia, Lithuania, Netherlands, Peru, Poland, Portugal, Romania, Russian Federation, Slovak... and more
GenesisCare USA
Bayer

Withdrawn

Darolutamide With Radium-223 or Placebo and the Effect on Radiological Progression-Free Survival for Patients With mCSPC (CARE)

Metastatic Prostate Cancer
Calithera Biosciences, Inc

Completed

Effect of Sapanisertib (MLN0128) on the QTc Interval in Participants With Advanced Solid Tumors

Advanced Solid Tumors

United States
Valerion Therapeutics, LLC

Terminated

VAL-1221 Delivered Intravenously in Ambulatory and Ventilator-free Participants With Late-Onset Pompe Disease

Pompe Disease

United States, United Kingdom
M.D. Anderson Cancer Center
Millennium Pharmaceuticals, Inc.

Withdrawn

Alisertib and TAK-228 in Participants With Human Papilloma Virus (HPV) Associated Malignancies

Malignant Neoplasms of Female Genital Organs | Malignant Neoplasms of Lip Oral Cavity and Pharynx | Malignant Neoplasms of Digestive Organs | Malignant Neoplasms of Male Genital Organs
Far Eastern Memorial Hospital

Unknown

Monitoring Radiobiological Effects in Thoracic Malignancy by Using Myocardial Perfusion Scan

Thoracic Neoplasms | Late Effect of Radiation

Taiwan
M.D. Anderson Cancer Center
National Cancer Institute (NCI); Department of Health and Human Services

Terminated

Wild Type p53 Adenovirus for Oral Premalignancies

Mouth Cancer

United States
Immorna Biotherapeutics, Inc.

Recruiting

Study to Evaluate JCXH-211 as Monotherapy in Patients With Malignant Solid Tumors

Malignant Solid Tumor | Cutaneous Tumor

China
Sir Mortimer B. Davis - Jewish General Hospital

Recruiting

Management of Oligoprogressive Castration Resistant Prostate Cancer (PCS X)

Castration-resistant Prostate Cancer | Metastatic Prostate Cancer

Canada
Amgen
MedImmune LLC

Terminated

A Phase 1 Study of AMG 211 in Participants With Advanced Gastrointestinal Cancer

GI Adenocarcinoma

Germany, Netherlands
Philip Morris Products S.A.

Completed

Exploratory THS 2.1 Biomarkers of Exposure Study (ZRHX-EX-01)

Smoking

Poland
Rapa Therapeutics LLC
Medical College of Wisconsin

Recruiting

RAPA-201 T Cell Therapy for Relapsed, Refractory Multiple Myeloma

Relapsed, Refractory Multiple Myeloma

United States
Bayer

Completed

Study to Gather Information About the Use of Healthcare Services and the Way the Disease is Cared for in Canadian Patients With Prostate Gland Cancer Which Spread Throughout the Body (REACTIVATE)

Prostate Cancer

Canada
Bayer

Completed

EPIX, a Study to Gather More Information About Characteristics of Patients and Other Factors Which May Contribute to Survival Over a Long Period of Time in Patients With Metastatic Castration-resistant Prostate Cancer (mCRPC) Treated With Radium-223 (Xofigo) (EPIX)

Metastatic Castration Resistant Prostate Cancer (mCRPC)

United States
Bayer

Completed

Radium-223 Dichloride Asian Population Study in the Treatment of CRPC Patients With Bone Metastasis

Prostatic Neoplasms

China, Singapore, Taiwan, Korea, Republic of
Bayer

Completed

A Drug Utilization Study of Radium-223 in Sweden

Neoplasms

Sweden
Institut für Diabetes-Technologie Forschungs- und...

Completed

System Accuracy Evaluation of 2 CE-marked Blood Glucose Monitoring System

Diabetes

Germany
Bayer

Active, not recruiting

Study to Gather Information on the Safety and How Radium-223 Dichloride, an Alpha Particle-emitting Radioactive Agent, Works Under Routine Clinical Practice in Taiwan in Patients With Castration-resistant Prostate Cancer (CRPC) Which Has Spread to the Bone (RAPIT)

Castration-resistant Prostate Cancer

Taiwan
University of Utah
Bayer

Completed

Radium-223 and Radiotherapy in Hormone-Naïve Men With Oligometastatic Prostate Cancer to Bone (RROPE)

Prostate Cancer Metastatic to Bone

United States
Bayer

Completed

Treatment Satisfaction With Ra-223 in Japan

Prostatic Neoplasms

Japan
Bayer

Terminated

A Research Called CREDIT Studies How Safe the Study Treatment Radium-223 is and How Well it Works in Chinese Men With Advanced Prostate Cancer That Has Spread to the Bones and Does Not Respond to Treatments for Lowering Testosterone Levels (CREDIT)

Bone Metastases | Metastatic Castration-resistant Prostate Cancer

China
Bayer

Completed

Pain Evaluation in Radium-223 Treated Castration Resistant Prostate Cancer Patients With Bone Metastases (PARABO)

Castration-Resistant Prostatic Cancer

Germany
Bayer

Completed

Re-treatment Safety of Radium-223 Dichloride in Castration-resistant Prostate Cancer With Bone Metastases

Prostatic Neoplasms

United States, Israel, Spain, Italy, Sweden, Norway, Finland
Bayer

Completed

Radium(223) Dichloride (Alpharadin) in Castration-Resistant (Hormone-Refractory) Prostate Cancer Patients With Bone Metastases

Prostatic Neoplasms

Belgium, Spain, Canada, France, Switzerland, Germany, United Kingdom, Denmark, Russian Federation, Sweden, Israel, Italy, Netherlands, Norway, Czech Republic, Finland, Poland, Ireland, Mexico
Bayer

Completed

Safety, Biodistribution, Radiation Dosimetry and Pharmacokinetics Study of BAY88-8223 in Japanese Patients

Prostatic Neoplasms

Japan
Arcturus Therapeutics, Inc.

Terminated

A Trial Evaluating the Safety and Effects of an RNA Vaccine ARCT-021 in Healthy Adults

Covid19 | Corona Virus Infection | SARS-CoV Infection

United States, Singapore
Hacettepe University

Completed

Precision of Three Different Scanbodies Used for Direct Digitalization Technique

Prosthesis User | Digitalism

Turkey
Kowloon Hospital, Hong Kong
The Hong Kong Polytechnic University

Completed

Robotic-assisted Locomotor Training on Mobility and Cardiopulmonary Function in Patients Suffering From Spinal Cord Injury

Spinal Cord Injury

China
University of Michigan Rogel Cancer Center

Completed

Phase II Trial Evaluating Axitinib In Patients With Unresectable, Recurrent Or Metastatic Head And Neck Cancer

Head and Neck Squamous Cell Carcinoma

United States
Pfizer

Completed

AG-013736 (Axitinib) In Patients With Poor Prognosis Acute Myeloid Leukemia (AML) Or Myelodysplastic Syndrome (MDS)

Myelodysplastic Syndrome | Acute Myeloid Leukemia (AML)

United States
Creative Medical Technology Holdings Inc

Not yet recruiting

Safety, Tolerability, and Effectiveness of Intramuscular Injection of CELZ-201-DDT for the Treatment of Chronic Lower Back Pain (ADAPT)

Chronic Low-back Pain | Degenerative Disc Disease

United States
Travere Therapeutics, Inc.

Recruiting

A Study to Investigate Safety and Effect of Sparsentan in Combination With SGLT2 Inhibition in Participants With IgAN (SPARTACUS)

Immunoglobulin A Nephropathy

United States, Hong Kong
Hadassah Medical Organization
Nexcella, Inc

Recruiting

NXC-201 (Formerly HBI0101) Multiple Myeloma

Dose Escalation and Safety

Israel
Suzhou Connect Biopharmaceuticals, Ltd.

Completed

Efficacy and Safety of CBP-201 in Patients With Moderate to Severe Persistent Asthma With Type 2 Inflammation

Moderate to Severe Persistent Asthma

United States, China, Hungary, Korea, Republic of, Poland
Fayoum University

Completed

GCF miRNA-223 , -214 Levels in Smokers and Nonsmokers Periodontitis Patients

Periodontitis, Adult

Egypt
Cerevel Therapeutics, LLC

Completed

PET Trial to Evaluate Target Occupancy of CVL-231 on Brain Receptors Following Oral Dosing

Schizophrenia

Belgium, United States
Medical College of Wisconsin
National Institute on Aging (NIA)

Completed

Network-Level Mechanisms for Preclinical Alzheimer's Disease Development

APOE 4

United States
Guangdong Hengrui Pharmaceutical Co., Ltd

Completed

A Trial of HRS-2261 in Healthy Subjects After Single and Multiple Oral Administration

Chronic Cough

China
OBI Pharma, Inc

Completed

Trial of Active Immunotherapy With OBI-833 (Globo H-CRM197) in Advanced/Metastatic Gastric, Lung, Colorectal or Breast Cancer Subjects

Metastatic Colorectal Cancer | Metastatic Lung Cancer | Metastatic Breast Cancer | Metastatic Gastric Cancer

Taiwan
miRagen Therapeutics, Inc.

Completed

Efficacy, Safety, and Tolerability of Remlarsen (MRG-201) Following Intradermal Injection in Subjects With a History of Keloids

Keloid

United States
Proteon Therapeutics

Completed

A Study of PRT-201 Administered Immediately After Radiocephalic Arteriovenous Fistula(AVF) Creation in Patients With Chronic Kidney Disease (CKD) (PATENCY-1)

Chronic Kidney Disease

United States
Bausch Health Americas, Inc.

Completed

Absorption and Systematic Pharmacokinetics of IDP-121 Lotion in Subjects With Acne Vulgaris

Acne

United States
Merrimack Pharmaceuticals
Sanofi

Completed

Phase I Safety Study of the Drug MM-121 in Patients With Advanced Solid Tumors Resisting Ordinary Treatment

Advanced Solid Tumors

United States
Vascular Biogenics Ltd. operating as VBL Therapeutics

Completed

A Study to Evaluate the Efficacy and Safety of VB-201 in Patients With Ulcerative Colitis

Ulcerative Colitis

Poland, Bulgaria, Hungary
Akros Pharma Inc.

Completed

Study of Safety, Tolerability and Pharmacokinetics of Single Oral JTT-251 Doses in Healthy and Type 2 Diabetic Subjects

Diabetes Mellitus

United States

3

Subscribe